Dr. Bela Ajtai
Claim this profileDent Neurologic Institute
Studies Alzheimer's Disease
Studies Mild Cognitive Impairment
3 reported clinical trials
5 drugs studied
Area of expertise
1Alzheimer's Disease
ApoE positive
ApoE negative
2Mild Cognitive Impairment
ApoE positive
ApoE negative
Affiliated Hospitals
Clinical Trials Bela Ajtai is currently running
BIIB080
for Alzheimer's Disease
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. Clinicians use the CDR-SB to measure several categories of dementia symptoms. The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of BIIB080. A description of how the study will be done is given below. Participants will receive either a low dose or high dose of BIIB080 or a placebo as an injection into the fluid around the spinal cord. A placebo looks like the study drug but contains no real medicine. The fluid around the spinal cord is called the cerebrospinal fluid. Participants will be in the study for 105 weeks, or a little over 2 years. This includes the screening and follow-up periods. Participants will be given BIIB080 or placebo once every 12 weeks for a total of 72 weeks. Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. After the screening period, most participants will visit the clinic every 6 weeks.
Recruiting0 awards Phase 24 criteria
Aducanumab
for Alzheimer's Disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Recruiting1 award Phase 31 criteria
More about Bela Ajtai
Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Bela Ajtai has experience with
- Masupirdine
- Aducanumab
- Placebo
- BIIB080
- BIIB080-matching Placebo
Breakdown of trials Bela Ajtai has run
Alzheimer's Disease
Mild Cognitive Impairment
Psychomotor Agitation
Alzheimer's Dementia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bela Ajtai specialize in?
Bela Ajtai focuses on Alzheimer's Disease and Mild Cognitive Impairment. In particular, much of their work with Alzheimer's Disease has involved ApoE positive patients, or patients who are ApoE negative.
Is Bela Ajtai currently recruiting for clinical trials?
Yes, Bela Ajtai is currently recruiting for 3 clinical trials in Amherst New York. If you're interested in participating, you should apply.
Are there any treatments that Bela Ajtai has studied deeply?
Yes, Bela Ajtai has studied treatments such as Masupirdine, Aducanumab, Placebo.
What is the best way to schedule an appointment with Bela Ajtai?
Apply for one of the trials that Bela Ajtai is conducting.
What is the office address of Bela Ajtai?
The office of Bela Ajtai is located at: Dent Neurologic Institute, Amherst, New York 14226 United States. This is the address for their practice at the Dent Neurologic Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.